Konica Minolta Inc. has agreed to pay $1bn to acquire Ambry Genetics as the first part of a new precision medicine platform, the companies announced July 6.
“This acquisition is the first in a series of strategic initiatives to secure a leading position for Konica Minolta in precision medicine,”, Konica Minotla Minolta CEO Shoei Yamana said in a release. “Together with Ambry, we will have the most comprehensive set of diagnostic technologies for mapping an individual’s genetic and biochemical makeup, as well as the capabilities to translate that knowledge into information the medical community can use to discover, prevent, and cost-effectively treat diseases